These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 17511772)

  • 1. Persistent expression of Aurora-A after neoadjuvant hormonal therapy as a predictor of a poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer.
    Furukawa J; Miyake H; Takenaka A; Hara I; Fujisawa M
    BJU Int; 2007 Aug; 100(2):310-4. PubMed ID: 17511772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced expression of heat shock protein 27 following neoadjuvant hormonal therapy is associated with poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer.
    Miyake H; Muramaki M; Kurahashi T; Yamanaka K; Hara I; Fujisawa M
    Anticancer Res; 2006; 26(2B):1583-7. PubMed ID: 16619575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neoadjuvant hormonal therapy for prostate cancer].
    Miyakita H
    Nihon Rinsho; 2005 Feb; 63(2):309-13. PubMed ID: 15714984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of micrometastases in pelvic lymph nodes detected by real-time reverse transcriptase polymerase chain reaction in patients with clinically localized prostate cancer undergoing radical prostatectomy after neoadjuvant hormonal therapy.
    Miyake H; Kurahashi T; Hara I; Takenaka A; Fujisawa M
    BJU Int; 2007 Feb; 99(2):315-20. PubMed ID: 17155986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of insulin-like growth factor binding protein-3 before and after neoadjuvant hormonal therapy in human prostate cancer tissues: correlation with histopathologic effects and biochemical recurrence.
    Miyata Y; Sakai H; Kanda S; Igawa T; Hayashi T; Kanetake H
    Urology; 2004 Jun; 63(6):1184-90. PubMed ID: 15183987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced expression of the secreted form of clusterin following neoadjuvant hormonal therapy as a prognostic predictor in patients undergoing radical prostatectomy for prostate cancer.
    Miyake H; Yamanaka K; Muramaki M; Kurahashi T; Gleave M; Hara I
    Oncol Rep; 2005 Nov; 14(5):1371-5. PubMed ID: 16211311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of thymidylate synthase expression in patients with prostate cancer undergoing radical prostatectomy.
    Li Y; Mizutani Y; Shiraishi T; Okihara K; Ukimura O; Kawauchi A; Nonomura N; Fukushima M; Sakai T; Miki T
    Urology; 2007 May; 69(5):988-95. PubMed ID: 17482957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: an early predictor of relapse or incomplete androgen suppression.
    Ryan CJ; Smith A; Lal P; Satagopan J; Reuter V; Scardino P; Gerald W; Scher HI
    Urology; 2006 Oct; 68(4):834-9. PubMed ID: 17070363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of neoadjuvant androgen deprivation on circulating prostate cells in the bone marrow of men undergoing radical prostatectomy.
    Wood DP; Beaman A; Banerjee M; Powell I; Pontes E; Cher ML
    Clin Cancer Res; 1998 Sep; 4(9):2119-23. PubMed ID: 9748128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y; Akaza H; Okada K; Yokoyama M; Moriyama N; Usami M; Hirao Y; Tsushima T; Sakamoto A; Ohashi Y; Aso Y;
    Int J Urol; 2004 May; 11(5):295-303. PubMed ID: 15147545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of hormonal therapy prior to radical prostatectomy on the recovery of quality of life.
    Namiki S; Saito S; Tochigi T; Kuwahara M; Ioritani N; Yoshimura K; Terai A; Koinuma N; Arai Y
    Int J Urol; 2005 Feb; 12(2):173-81. PubMed ID: 15733112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal duration of neoadjuvant androgen withdrawal therapy before radical prostatectomy in clinically confined prostate cancer.
    Gleave ME; Goldenberg SL; Jones EC; Bruchovsky N; Kinahan J; Sullivan LD
    Semin Urol Oncol; 1996 May; 14(2 Suppl 2):39-45; discussion 46-7. PubMed ID: 8725890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Difficulties in interpreting specimens after neoadjuvant hormonal therapy and radiation with illustration of neuroendocrine differentiation.
    Civantos F
    Mol Urol; 2000; 4(3):117-21; discussion 123. PubMed ID: 11062365
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
    Lee CT; Capodieci P; Osman I; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
    Clin Cancer Res; 1999 May; 5(5):977-83. PubMed ID: 10353729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen deprivation with salvage surgery for radiorecurrent prostate cancer: results at 5-year followup.
    Garzotto M; Wajsman Z
    J Urol; 1998 Mar; 159(3):950-4; discussion 954-5. PubMed ID: 9474190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of potential molecular markers in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
    Miyake H; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
    Urol Oncol; 2010; 28(2):145-51. PubMed ID: 18848789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer.
    Francini G; Paolelli L; Francini E; Pascucci A; Manganelli A; Salvestrini F; Petrioli R
    Eur J Surg Oncol; 2008 Feb; 34(2):216-21. PubMed ID: 17502132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy.
    Kroepfl D; Loewen H; Roggenbuck U; Musch M; Klevecka V
    BJU Int; 2006 May; 97(5):985-91. PubMed ID: 16643480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No residual tumor in a radical prostatectomy specimen after neoadjuvant hormonal therapy for localized prostate cancer.
    Noguchi M; Noda S; Nakashima O; Kojiro M
    Oncol Rep; 2002; 9(5):1075-80. PubMed ID: 12168076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience.
    Debruyne FM; Witjes WP
    Mol Urol; 2000; 4(3):251-6;discussion 257. PubMed ID: 11062381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.